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© 2012 The Japan Society of Histochemistry and A novel alanine:glyoxylate aminotransferase (AGT) mutation involved in primary hyperoxaluria
type 1 (PH1) was studied in Japanese patients. Two mutations in exon 7, c.751T>A and
c.752G>A, lead to a W251K amino acid substitution. Proband 1 (patient 1) was homozygous
for the W251K mutation allele (DDBJ Accession No. AB292648), and AGT-specific activity
in the patient’s liver was very low. To reveal the cause of the low enzymatic activity, the
intracellular localization of AGT (W251K) was studied using immunohistochemistry and
immunoelectron microscopy. The latter analysis showed that patient 2 had only one-fifth of
the normal AGT expression per catalase, suggesting impairment of AGT (W251K) dependent
transport into peroxisomes. Peroxisomal transport of human AGT is believed to be dependent
on the presence of the type 1 peroxisomal targeting sequence. The C-terminal tripeptide of
AGT, KKL is necessary for peroxisomal targeting. In cultured cells, EGFP-AGT (W251K)
localized both in the peroxisome and cytosol. These results were consistent with the data
obtained from liver analysis of patient 2. The subcellular distribution of AGT (W251K) and
the results from a random mutagenesis study suggest that KKL is necessary for peroxisomal
targeting of human AGT, but additional signal other than KKL may be necessary.
Key words: human liver alanine:glyoxylate aminotransferase (AGT), AGT (W251K), peroxisomes,
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I. Introduction
Human alanine:glyoxylate aminotransferase (AGT;
EC2.6.1.44), localized to liver peroxisomes, has a broad
substrate specificity and uses glyoxylate as the preferred
amino acceptor [11]. AGT catalyzes the formation of glycine
and prevents the formation of oxalate from glyoxylate. In
humans, hereditary insufficiency of AGT results in a rare
disorder in which excess amounts of glyoxylate is converted
to oxalate. This disorder, known as primary hyperoxaluria
type 1 (PH1; MIM259900), is characterized by hyper-
oxalemia and hyperoxaluria with massive calcium oxalate
deposition throughout the entire body [2].
PH1 is a rare autosomal-recessive disorder caused
by a deficiency of the liver-specific pyridoxal-phosphate-
dependent enzyme AGT. The AGT gene (AGXT) mutation
that underlies this disorder has been reported [7, 8, 13],
including studies of PH1-specific mutations (G41R, F152I,
G170R, and I244T) in European and North American
patients [3, 17], and a PH1-specific mutation (S205P) in
Japanese patients [10]. Over 140 mutations have been
identified in PH1 patients worldwide [17].
In the present study, we describe a new mutation in
AGXT that was identified in five Japanese PH1 patients.Kawai et al. 122
This new AGXT mutation involved two mutations in exon
7: c.751T>A mutation and c.752G>A mutation, resulting in
a Trp (W) 251 and a Lys (K) amino acid substitution. These
PH1 patients had low AGT-specific activity. We examined
the subcellular distribution of immunoreactive AGT protein
in the livers of the patients.
We also describe a pEGFP-AGT random mutagenesis
system by which randomly mutated AGT proteins are
created, and their localization was determined in human
fibroblast cells. Data obtained from these experiments
suggest the presence of unknown signals other than the type
1 peroxisomal targeting sequence (PTS1) in AGT.
II. Materials and Methods
Chemicals and antibodies
Rabbit anti-chicken IgG-gold colloidal particles (5 nm)
and goat anti-rabbit IgG, F(ab’)2 specific-gold colloidal
particles (15 nm) were purchased from EY Laboratories
Inc. (San Mateo, CA, USA). Chicken anti-AGT antibody
was prepared by Sawady Technology Co., Ltd. (Tokyo,
Japan). The synthesized N-terminal 20-amino acid peptide
of AGT was used as the antigen. LR White reagent
(TAAB Laboratories Equipment Ltd., Reading, UK) was
used as the hydrophilic embedding agent. Uranylacetate
dihydrate, trisodium citrate dihydrate and lead (II)-nitrate
were purchased from Merck Japan Inc. (Tokyo, Japan). A
Prolong Antifade Kit was purchased from Molecular
Probes Inc. (Eugene, OR, USA) and goat serum was pur-
chased from Vector Laboratories Inc. (Burlingame, CA,
USA). All other chemicals used for immunochemistry and
electron microscopy were of ultra-pure grade.
L-Alanine, glyoxylate and pyridoxal 5'-phosphate were
purchased from Wako Pure Chemical Industries Ltd. (Osaka,
Japan), NADH was purchased from Oriental Yeast Co., Ltd.
(Tokyo, Japan) and L-lactate dehydrogenase was purchased
from Boehringer Mannheim GmbH (Ingelheim, Germany).
All other chemicals were of ultra-pure grade and were
obtained from Nacalai Tesque Inc. (Kyoto, Japan).
Subjects
This study protocol was approved by both Ethics
Committees at the Medical School of Fukuoka University
and Gunma University Graduate School of Medicine.
Informed consent was obtained from all patients for the
collection of tissue samples.
Family 1: Proband 1 (patient 1) was a 45-year-old
woman who was diagnosed with nephrolithiasis at the age
of 25, and had been maintained on dialysis therapy for 6
years prior to the study. The patient underwent liver
transplantation, and received her daughter’s liver. Liver
biopsy samples from proband 1 and her daughter were
examined for AGXT gene mutations and for AGT-specific
catalytic activity.
Family 2: The other liver samples were obtained from
members of another family, including a 6-year-old girl
(patient 2) who was the proband, her 9-year-old sister
(patient 3), their 33-year-old mother (patient 4), and their
29-year-old father (patient 5). Analysis of the AGXT gene
in this family will be reported elsewhere. We examined liver
AGT protein expression and AGT-specific catalytic activity
in these liver samples, and performed immunohistochemical
and immunoelectron microscopic analyses.
Normal control: A human liver was obtained at autopsy
from a 59-year-old male who died from lung cancer and
who had no history of urolithiasis. This sample was used
as a normal control sample.
RNA isolation
Total RNA was extracted and isolated from patient
liver samples with TRIZOL reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
First-strand cDNA synthesis
Full-length first-strand cDNA was generated from the
mRNA templates with Oligo (dT) primers using Ready-
To-GoTM You-Prime First-Strand Beads (GE Healthcare
Bio-Science Corp., Piscataway, NJ, USA) according to the
manufacturer’s instructions.
PCR amplification
cDNA samples were amplified by PCR using specific
sense (NF3) and antisense (CR3) primers. The primer
sequences used are as follows: sense (NF3), 5'-TGCTGGG
AAATATTCCAGGCTTTG-3', and antisense (CR3), 5'-GC
CAGGCCCTTTATTAAACATTCCC-3'. KOD-Plus DNA
polymerase (TOYOBO, Osaka, Japan) was used. The PCR
products were subjected to electrophoresis on a 1% agarose
gel, and the expected size of the amplified PCR product
was 1540 bp.
Cloning of the PCR products and sequencing
The PCR products were cloned using Target CloneTM
Plus (TOYOBO, Osaka, Japan) according to the manufac-
turer’s instructions. The plasmids were purified using a
QIAprep Spin Miniprep Kit (QIAGEN, Tokyo, Japan). The
PCR products were confirmed by DNA sequencing of the
amplified products using primers flanking each region as
follows: sense (NF3), 5'-TGCTGGGAAATATTCCAGGCT
TTG-3; sense (SF1), 5'-ATCCAGTACGTGTTCCAGACC
A-3'; sense (SF2), 5'-GCTGGCTATGACTGGAGAGACA-
3'; and sense (SF4), 5'-GTGGATTCGGTGGCATCCCTG
GG-3', using an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Warrington, UK) with a BigDye
Terminator Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA).
Genomic DNA isolation
Genomic DNA was extracted from peripheral blood
samples using a MagExtractor-Genome (TOYOBO, Tokyo,
Japan), according to the manufacturer’s instructions. Exon
7 of the AGXT gene was amplified as previously described
[16]. The genomic DNA sequences were determined as
follows: sense, 5'-GGGGAGAGAAAGGGGCACACAGAMistargeting of Peroxisomal Enzyme in PH1 123
GT-3', and antisense, 5'-TGGGGCTVTAGTTGGGGTTCT
TGAG-3', using a BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA).
Immunohistochemistry
Liver specimens were obtained from patients 2 and 4
by surgical biopsies. They were fixed in 4% paraformalde-
hyde and 0.1% glutaraldehyde in 0.1 M sodium phosphate
buffer at pH 7.4, then paraffin-embedded and sectioned.
Sections were deparaffinised, blocked with 2% goat serum,
incubated with chicken anti-AGT (1:100) at 4°C overnight,
and washed three times with 0.1% Triton/PBS for 5 min.
Subsequently, sections were incubated with biotinylated
anti-chicken  IgG  antibody  (1:200)  for  1  hr  at  room  tem-
perature, washed as described above, and stained with DAB
(3,3'-diaminobenzidine tetrahydrochloride) using an ABC
Elite Kit (Vector Laboratories, Burlingame, CA, USA)
according to the manufacturer’s instructions. Before mount-
ing, sections were counter-stained with haematoxylin.
Immunoelectron microscopy
The biopsied liver specimens were fixed for 12 hr at
4°C in 4% paraformaldehyde and 0.1% glutaraldehyde in
0.1 M sodium phosphate buffer at pH 7.4. The fixed sections
were embedded in acrylic resin LR-white. Thin sections
(70–80 nm thick) were cut on a Leica Ultracut S (Leica
Microsystems Japan, Tokyo, Japan), and the ultra-thin
sections were mounted on nickel grids. The grids were placed
on a drop of PBS to rinse the mounted sections, and then
transferred onto a drop of 10% H2O2 for 20 min at room
temperature for etching. The grids were washed with PBS,
and incubated on a drop of 1% bovine serum albumin in
PBS (1% BSA/PBS buffer) for blocking. The sections were
incubated for double-immune staining simultaneously with
25-fold diluted chicken anti-human AGT serum in 1%
BSA/PBS and 100-fold diluted rabbit anti-human catalase
IgG (0.03 mg/ml 1% BSA/PBS) overnight at 4°C in a
humidified chamber. The sections were then washed with
1% BSA/PBS, and incubated with rabbit anti-chicken IgG
colloidal gold (5-nm particles; 1–2 µg/ml) and goat anti-
rabbit IgG colloidal gold (15-nm particles; 1–2 µg/ml) for
1 hr at room temperature. Pre-immune chicken serum and
rabbit IgG were used for control experiments. After the
sections were washed with PBS, the sections were fixed
for 10 min at room temperature in 2% glutaraldehyde in
1/15 M sodium phosphate buffer at pH 7.4. The sections
were then washed with distilled water and stained with
2% uranyl acetate. Next, they were subjected to adsorption
staining with lead citrate. The stained sections were viewed
under a JEM-2000EXII electron microscope (JEOL, Tokyo,
Japan) at an acceleration voltage of 80 kV.
Enzyme preparation
The biopsied liver specimens from PH1 patients 1 to
5, the donor and the autopsy control were immediately frozen
in liquid nitrogen after biopsy. All samples were kept on
dry ice until homogenization, which was performed on ice
in nine volumes of 10 mM potassium phosphate buffer at
pH 8.2 containing 0.05% Triton X-100 (homogenization
buffer) in a Potter-Elvehjem glass homogenizer with a Teflon
pestle. The homogenates were centrifuged at 100,000×g for
30 min at 4°C. The supernatants were collected for analysis
as the liver extracts, and stored at −30°C until use.
Alanine:glyoxylate aminotransferase assay
Alanine:glyoxylate aminotransferase was assayed
using the method of Okuno et al. [11]. The standard assay
mixture contained 40 mM L-alanine, 5 mM glyoxylate,
0.05 mM pyridoxal 5'-phosphate, 100 mM potassium phos-
phate buffer at pH 8.2, and 50 µl of 10-fold diluted liver
extract, unless otherwise described. The enzyme reaction
was carried out at 37°C for 30 min or 1 hr in a total vol-
ume of 800 µl. The reaction was stopped by adding 100 µl
of 25% trichloroacetic acid. Denatured protein was removed
by centrifugation at 1,500×g for 5 min. The supernatant
(450 µl) was transferred to a fresh tube and neutralized with
50 µl of 2 M KOH, and the neutralized solution was added
to 450 µl of 2 M Tris/HCl at pH 8.2, followed by addition
of 0.25 µmol NADH and 12.5 µg of lactate dehydrogenase.
The mixture was incubated for 30 min at room temperature,
and the resultant decrease in NADH absorption was meas-
ured with a Shimadzu Spectrophotometer UV-160A (Kyoto,
Japan) at 340 nm and compared with a blank sample.
Glyoxylate or enzyme (10-fold diluted liver extracts) was
added to the blank sample after stopping of the reaction.
Protein assay
Protein concentrations were determined by the method
of Bradford [1] using a Bio-Rad Protein AssayTM or a RCDC
protein assayTM (Bio-Rad Laboratories, Hercules, CA, USA).
Bovine serum albumin was used to prepare the standard
curve.
pEGFP-SKL, pEGFP-AGT, pEGFP-AGT (W251K) 
expression plasmid constructs
The pEGFP-SKL expression plasmid used in this study
has been previously described [6]. The pEGFP-AGT,
pEGFP-AGT (W251K) and AGT mutation constructs were
prepared from pEGFP-SKL. In addition to these naturally
occurring mutants, over 100 AGT mutants were developed
using a Diversity PCR Random Mutagenesis Kit (BD
Biosciences, Tokyo, Japan), according to the manufacturer’s
instructions.
Cell culture, transfection and analysis of transfectants
The human fibroblast cell line, HUC-F2, was cultured
in GlutaMax medium (GIBCO) supplemented with 10%
fetal calf serum under 5% CO2 in air. DNA transfection into
cells was performed using the Nucleofector System (Amaxa
Biosystems, Cologne, Germany) for normal human adult
dermal fibroblasts with Program U-23. After 2 days of
culture, cells were fixed in 4% paraformaldehyde in PBS
at pH 7.4. Cells transfected with GFP constructs were
also fixed and the expressed protein was visualized underKawai et al. 124
an immunofluorescent light microscope (Olympus DP70,
Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using Dr. SPSS Ver
8 (SPSS Inc., Chicago, IL, USA). One-factor ANOVA was
used to analyse the number of gold-labelled peroxisomes in
patients 2 and 4, and the control. Tukey’s test was used to
identify statistically significant differences. P-values less
than 0.05 were regarded as statistically significant.
III. Results
AGXT gene analysis
The molecular basis of PH1 was examined by analyzing
the entire coding sequence of AGXT. Patient genotypes
are shown in Table 1. Mutation analysis of the AGXT gene
in patient 1 (Japanese PH1 patient) revealed three novel
mutations. One of these novel mutations, c.676C>A, is
considered to be a silent mutation. The other two novel
mutations, c.751T>A and c.752G>A, lead to homozygous
mutations with Trp (W) 251 Lys (K) amino acid replace-
ments. Gene analysis of the AGXT gene from mRNA and
genomic DNA yielded identical results. The W251K
mutation found in the Japanese PH1 patient was novel, and
was registered as DDBJ Accession No. AB292648.
AGT-specific activity in the liver of PH1 patients
Table 1 shows the AGT-specific activity of the biopsied
liver extracts. When one allele of the AGXT gene was
W251K and the other was wild-type (Patient 1’s daughter),
the specific AGT enzymatic activity was about 60% that of
the normal control sample. Similar to patient 1’s daughter,
patients 4 and 5 were heterozygotes of AGXT with one
mutated allele, resulting in activities half of that of the
normal control. When one allele of the AGXT gene was
W251K and the other was a premature stop codon (Patients
2 and 3), AGT-specific activity was about 16% and 11%
that of the normal control, respectively. When the two
alleles were homozygous for W251K (Patient 1), the spe-
cific activity was about 22% of that of the normal control.
These results were in agreement with the AGXT geno-
type. Therefore, the AGXT gene mutation resulted in the
production of AGT protein with low AGT-specific activity,
leading to PH1.
Intracellular localization of AGT protein in liver specimens 
from PH1 patients
To determine the intracellular localization of AGT in
liver specimens from PH1 patients, we performed immuno-
histochemical staining using anti-AGT antibody. Figure 1
shows the localization of AGT in specimens obtained from
the normal control (Fig. 1A and B), patient 4 (Fig. 1C and
D) and patient 2 (Fig. 1E and F). In the normal control
sample, AGT protein was expressed by the wild-type
heterogeneous AGXT gene and clearly was localized to the
peroxisome. In patient 4, the AGT protein was expressed
by the AGXT gene (wild-type and W251K) and localized
predominantly to the punctuates (possibly peroxisomes) with
weak staining throughout the cytosol. In contrast, in patient
2, the AGT protein was expressed by the AGXT gene
(W251K and premature stop) and did not clearly localize
to the punctuates (peroxisomes), and was instead scattered
faintly throughout cytosol.
Immunoelectron microscopy analysis
To quantitatively determine the distribution of AGT,
we performed double immunoelectron staining for AGT and
catalase in liver specimens from the normal control, and
patients 2 and 4. Catalase was stained with 15-nm gold
particles and AGT was stained with 5-nm gold particles.
Both types of gold particles were localized to the peroxi-
somes, as shown in Figure 2. The number of catalase gold
particles (large particles) in each peroxisome was counted
and determined to be 6.8±3.9, 6.5±3.5 and 5.6±2.6 for the
normal control subject, patient 4 and patient 2, respectively
(Table 2). ANOVA analysis showed that these numbers were
not significantly different, indicating that peroxisome pro-
liferation was not affected by the W251K AGT mutation.
This showed that gold staining for catalase could be used
as a quantitative marker of peroxisomes. The number of
AGT gold particles (small particles) per peroxisome was
93.3±43.4, 42.1±23.3 and 12.9±7.7 for the normal control
subject, patient 4 and patient 2, respectively. These numbers
were significantly different based on the ANOVA and
Tukey’s test (Table 2). We also calculated the number of
AGT gold particles per catalase gold particle, and found it
to be 16.2±9.2, 7.2±3.4 and 3.0±1.9 for the normal control
subject, patient 4 and patient 2, respectively. These numbers
were significantly different based on the ANOVA and
Tukey’s test (Table 2). These results clearly suggest that
Table 1. AGT-specific activity in the liver extracts






Normal control 59 810 100 Wild-type Wild-type
1 Patient 1 45 178 22 W251K W251K
1 Patient 1’s daughter (donor) — 478 59 W251K Wild-type
2 Patient 2 6 130 16 W251K premature stop
2 Patient 3 9 87 11 W251K premature stop
2 Patient 4 33 452 56 W251K Wild-type
2 Patient 5 29 405 50 Premature stop Wild-typeMistargeting of Peroxisomal Enzyme in PH1 125
targeting of AGT to peroxisomes is impaired in patients 2
with W251K mutation.
Intracellular localization of transfected mutant AGT protein
Expression vectors containing mutant AGXT fused
with the GFP gene were transfected into the human fibro-
blast cell line, HUC-F2. The intracellular distribution of
wild-type or mutant AGT was determined by fluorescence
microscopy (Fig. 3). The proteins from pEGFP-SKL
(Fig. 3A) and pEGFP-AGT (wild-type) correctly localized
to the peroxisomes (Fig. 3B). However, EGFP fused with
AGT-W251K, the gene with one amino acid substitution,
seemed to localize both in the peroxisomes and the cytosol
(Fig. 3C). While many distinctive punctuates, which might
correspond to the peroxisomes, could be observed, smear
signals were also detected throughout the cytoplasm, sug-
gesting that some population of the AGT-W251K proteins
failed to correctly localize to peroxisomes.
Random mutagenesis of the AGT gene
Next, the AGT gene was randomly mutated, transfected
into HUC-F2 cells, and the localization of the resultant AGT
protein was examined (Fig. 4). Nearly half of the mutated
AGT proteins were truncated due to a stop codon, and were
Fig. 1. Immunohistochemical staining with anti-AGT antibody of liver specimens obtained from the normal control and patients with PH1.
Liver specimens from the normal control (A and B), patient 4 (C and D) and patient 2 (E and F) were stained with anti-AGT antibody by immu-
nohistochemical method and counterstained with haematoxylin. B, D and F are enlarged images respectively for A, C and E. Bar=50 µm.Kawai et al. 126
excluded from the analysis. Four targeting patterns, perox-
isome only (Fig. 4A), peroxisome and cytosol (Fig. 4B), no
targeting (Fig. 4C), or unknown (Fig. 4D), were observed
in this experiment (Table 3, Fig. 4). The clones M11-15
(V93A, K225R) and M11-21 (S19T, Y134C), which had
two amino acid substitutions, had full-length sequences
including the peroxisomal targeting sequence PTS1 (KKL),
and targeted correctly to the peroxisomes (Table 3).
Moreover, although the clone M11-12 had five amino
acid substitutions (I37V, D58E, S81P, P130H, K227R),
the expressed protein correctly localized to peroxisomes
(Fig. 4A). The clone M14-21 had four amino acid sub-
stitutions (K209R, L219R, E281V, L298P), and although
it expressed full-length AGXT and had an intact PTS1
(KKL), the fusion protein failed to correctly localize to the
peroxisomes (Fig. 4B). The clone M10-19 had two amino
acid replacements (I244V, L302P) (Table 3). Although this
clone expressed full-length AGXT and had an intact
Table 2. Number of gold-labelled catalase and AGT proteins per peroxisome. The numbers of catalase-gold and AGT-gold particles were
counted in each peroxisome by double immune-gold electron microscopy.
Values represent means±SD; N: number of peroxisomes counted.
*: significantly different (p<0.05) from the control.
**: significantly different (p<0.05) from patient 4.
Age (years) Catalase-gold AGT-gold AGT-gold/Catalase-gold N
Control 59 6.8±3.9 93.3±43.4 16.2±9.2 29
Patient 4 33 6.5±3.5 42.1±23.3* 7.2±3.4* 67
Patient 2 6 5.6±2.6 12.9±7.7*, ** 3.0±1.9*, ** 36
Fig. 2. Peroxisomal localization of AGT and catalase determined by immunoelectron microscopy. AGT was stained by 5-nm gold particles
(small particle) and catalase by 15-nm gold particles (large particle). Both types of gold particles were localized in peroxisomes. Both types of
gold particles were counted in each peroxisome, and numbers of each particle are listed in Table 2. A: normal liver; B: AGT heterozygous liver
(patient 4); C: compound heterozygous liver (patient 2). Bar=200 nm.
Fig. 3. Immunofluorescence analysis of the intracellular distribution of EGFP-fusion protein. EGFP-fusion protein was transfected to human
fibroblast cells with the following constructs. A: pEGFP-SKL; B: pEGFP-AGT (wild-type); C: pEGFP-AGT (W251K). Bar=2 µm.Mistargeting of Peroxisomal Enzyme in PH1 127
peroxisomal targeting sequence PTS1 (KKL), it did not
localize to any specific organelle (Fig. 4C). The clone M14-
7 (P10S, L166P, F238S, K245E) also had a full-length
AGXT sequence and had the KKL motif, but this mutated
protein localized in particles different from peroxisomes
(Fig. 4D).
IV. Discussion
In the present study, mutation analysis of the AGXT
gene in Japanese PH1 patients revealed a novel mutation,
W251K (c.751T>A; c.752G>A). PH1 patient 1 was homo-
zygous for W251K. The cDNA sequencing data were
consistent with the genomic DNA analysis. PH1 patient 4
was a heterozygote with a normal allele and an abnormal
W251K allele. PH1 patients 2 and 3 were heterozygotes
with W251K and a premature stop. Other mutations in PH1
have also been reported in Japanese people [10]. Because
PH1 patients have a W251K mutation in the AGXT gene,
AGT-specific activity in their livers was very low. As patient
4 showed approximately half of the activity found in the
normal control subject, patient 4 was not considered to be
Fig. 4. The intracellular distribution pattern of mutant AGT made from random mutagenesis proteins in transfected human fibroblast cells.
Human fibroblast cells were transfected with the constructs clones M11-12 (A), M14-21 (B), M10-19 (C) and M14-7 (D) (please refer to
Table 3) and after 48 hr the cells were visualized for autofluorescence of GFP (A, B, C, D). Bar=2 µm.
Table 3. Subcellular distribution of GFP-AGT fusion proteins from random AGT mutagenesis
Px: peroxisomes.
Clone name Mutation number C-terminal 
amino acids Amino acid change Subcellular distribution
M11-3 1 KKL F68L Px
M11-12 5 KKL I37V, D58E, S81P, P130H, K227R Px
M11-15 2 KKL K225R, V93A Px
M11-21 2 KKL S19T, Y134C Px
M14-14 4 KKL S271C, E285G, R289H, V358A Px
M14-7 4 KKL P10S, L166P, F238S, K245E unknown
M14-21 4 KKL K209R, L219R, E281V, L298P Px and cytosol
M11-18 3 KKL A2T, F100S, M230V Px and cytosol
M10-19 2 KKL I244V, L302P notargetingKawai et al. 128
hyperoxaluric. Patients 1, 2 and 3 had approximately 10%
to 20% of the AGT-specific activity seen in the normal
control subject, and they were considered to have typical
hyperoxaluria.
AGT protein localization was studied by immuno-
histochemical microscopy and immunoelectron microscopy.
AGT (W251K) was partially localized to the liver peroxi-
somes (Figs. 1 and 2), but the number of the molecules was
low (Fig. 2B and 2C, Table 2). The number of catalase gold
particles was not different between the normal control
subject, patient 2 and patient 4 (Table 2). This data indicate
that the quantity of catalase per peroxisome is not different
between normal control subjects and PH1 patients. However,
the ratio of AGT gold particles versus catalase gold particles
was 16.2, 7.2, and 3.0 for the normal control subject, patient
4, and patient 2, respectively (Table 2). The number of AGT
gold particles localized to peroxisomes in patient 4 was
approximately half that of the normal control subject; that
in patient 2 was approximately one-fifth of that in the normal
control subject (Table 2). These data are consistent with
those on AGT enzymatic activity (Table 1).
Peroxisome-targeting signals (PTS) have been reported
as PTS1 [4, 14] and PTS2. PTS1 is a C-terminal amino acid
sequence motif that contains SKL (Ser-Lys-Leu), and PTS2
is a N-terminal sequence motif. AGT belongs to the PTS1
group of proteins [5, 9], but instead of having the typical
C-terminal motif, it has a KKL (Lys-Lys-Leu) [15]. After
the fusion protein (pEGFP-KKL) was constructed and
expressed, the KKL motif did not function as a PTS (data
not shown), but GFP-SKL did (Fig. 3). This demonstrated
that the KKL motif is essential, but insufficient in targeting
AGT to peroxisomes, and that proteins containing the KKL
motif may contain an additional, but yet unknown, amino
acid motif. The 251W mutation is located far from the KKL
C-terminal motif, but it appears to affect AGT peroxisomal
targeting. Substitution of 251W with K might lower the
affinity for targeting machineries. In the hepatocytes of
patient 4, normal and mutated AGT (W251K) might compete
for the machinery involved in peroxisomal targeting, and
the normal AGT may be more effectively transported by
the machinery, resulting in AGT levels half that of the
normal control subject in patients with the 251W mutation.
On the other hand, patients 2 and 3 only expressed the
W251K AGT protein, which may have low affinity for the
targeting machinery, and may be slowly or inefficiently
transported, resulting in the low peroxisomal localization of
AGT (W251K) (Table 2). The inadequate targeting of AGT
(W251K) to peroxisomes might be responsible for the
hyperoxalosis.
The fusion proteins expressed from the pEGFP-
AGTwild and pEGFP-SKL constructs localized to peroxi-
somes. The EGFP-AGT (W251K) protein was targeted to
peroxisomes and the cytosol. These results were consistent
with the results from the immunoelectron microscopic
analysis of patients 2 and 4. The results obtained from the
random mutagenesis experiment demonstrated that the PTS1
motif KKL might be essential, but insufficient in targeting
AGT to peroxisomes. Two of the three amino acids, KKL
of the AGT C-terminus were same with those of the three
amino acids, SKL necessary for peroxisomal targeting.
However, KKL is insufficient for correct peroxisomal tar-
geting, because KKL fused with EGFP failed to localize
to peroxisomes (data not shown). Moreover, in the random
mutagenesis study, an AGT protein with five mutations was
transported successfully into peroxisomes (Fig. 4A), while
those with only two mutations failed to localize correctly
(Fig. 4B). These results suggest that the portion between
residues 238 and 270 is important in AGT transport into
peroxisomes.
AGT protein has a pentapeptide motif, WXXXF/Y,
which is known to be critical for the import of peroxisomal
matrix proteins by the PTS1 receptor Pex5 [12]. This motif
exists at 246 WLANF 250 in the AGT protein. It is possible
that amino acid mutations between positions 244 and 251,
which is in close proximity to this motif, could affect
targeting to peroxisomes.
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